Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.
Status:
Terminated
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
Pilot multicentre, open label study with the aim to evaluate antitumor activity in term of
the sum of complete and partial response (O.R.R.) of chemotherapy (cyclophosphamide and
fludarabine) and rituximab, followed by zevalin radioimmunotherapy and response duration
(Time to relapse or progression)and to evaluate the safety of the treatment as acute and late
toxicity.
Secondary objective is to evaluate the overall survival (OS) and the event-free survival
(EFS).